Protara Therapeutics is trading 5.5% up at $4.02 as it bounces from recent weakness and benefits from a broader risk-on move in U.S. equities.
- The move appears tied to improving market sentiment and a recovery in smaller biotech names after the recent selloff.
- No fresh, company-specific catalysts have been reported today; the price action reflects broader market trends.